BBOT
Palo Alto
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3K╬▒ malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, visit bridgebiooncology.com.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Total funding: $461.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2025)
- Ticker: nasdaq:BBOT
- Website: bridgebiooncology.com
Industries & Categories
Biopharma, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/bbot-79671 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.